Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AMLX
AMYLYX PHARMACEUTICALS, INC.
NASDAQ
$34.74
▼ DOWN 6.56% (-2.44)

KEY STATISTICS

Market Cap$3.86 B
52w High$41.14
52w Low$9.14
Dividend Yield5.64%
FrequencyQuarterly
P/E-23.16
Volume1.36M
Shares Out.111.19M

COMPANY

LEADERSHIP

Joshua Cohen
CHIEF EXECUTIVE
Joshua Cohen

COMPENSATION 2026

Salary$686,200
Stock Awards$650,226
Incentive Plan Pay$548,098
All Other Comp.$17,500
Total$2,719,807

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 7, 2022
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
136

PRICE TARGET

Target High$57.00
Target Low$42.00
Target Median$55.00
Target Consensus$52.20

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$59.43K
NOV
5
THU

PRICE

$34.74 ▼ DOWN 6.56% (−$2.44)
$35.00$36.00$37.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM34.74

About Amylyx Pharmaceuticals, Inc.

https://amylyx.com ↗

Amylyx Pharmaceuticals, a Cambridge-based clinical-stage biopharma founded in 2013, develops therapeutics like AMX0035 for ALS and other neurodegenerative diseases.

INDUSTRY

Biotechnology

A PRODUCT AMYLYX PHARMACEUTICALS, INC. IS KNOWN FOR

avexitide
avexitide

Amylyx's leading investigational first-in-class GLP-1 receptor antagonist is in Phase 3 for post-bariatric hypoglycemia, marking the company's primary focus after withdrawing its former ALS drug.

COMPETITORS

COMPETITOR
ACAD COMPARE
BIIB COMPARE
DNLI COMPARE
IONS COMPARE
NBIX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
131
LISTED HERE
22
RANKED BY POSITION SIZE
VTS.AX
0.00% · 3.2M
IWM
0.12% · 2.6M
D5BM.DE
0.38% · 1.0M
XPH
3.93% · 619.6K
SCHA
0.08% · 470.2K
FYC
0.51% · 211.5K
SBIO
1.98% · 137.2K
DFMC
0.05% · 117.1K
PRFZ
0.10% · 83.9K
NUSC
0.19% · 77.0K
FFSM
0.09% · 65.0K
FSCC
0.65% · 58.8K
RSSL
0.11% · 49.4K
GSSC
0.13% · 39.7K
BBSC
0.11% · 23.7K
BBC
1.53% · 21.5K
PILL
2.64% · 17.5K
URTY
0.04% · 4.2K
RFLR
0.14% · 3.8K
ESSC
0.18% · 3.2K
TNXT
0.15% · 772
USFMDN.MX
0.01% · 370

INSTITUTIONAL OWNERSHIP

SHARES OWNED
70.56%
HOLDERS
269
TOP 12 OF 269 · RANKED BY POSITION SIZE
Fmr LLC
16.7M sh · $300.43M
Blackrock, Inc.
9.1M sh · $109.38M
Perceptive Advisors LLC
9.0M sh · $121.66M
Adage Capital Partners Gp, L.L.C.
6.8M sh · $92.64M
Tcg Crossover Management, LLC
6.2M sh · $112.14M
Vanguard Group Inc
5.8M sh · $70.12M
Commodore Capital LP
5.7M sh · $78.53M
Janus Henderson Group Plc
5.0M sh · $69.26M
Saturn V Capital Management LLC
4.6M sh · $83.05M
First Light Asset Management, LLC
3.4M sh · $45.61M
Morgan Stanley
3.1M sh · $56.23M
Driehaus Capital Management LLC
3.1M sh · $37.56M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Chris Jacobs
Chris Jacobs
Purchase
2022-10-12
 Christopher L. Jacobs
Christopher L. Jacobs
Purchase
2022-10-12

INSIDER TRADES

★
OFFICER: CHIEF LEGAL OFFICER
Mazzariello Gina
Purchase · 21.3K shares
2026-08-18
★
DIRECTOR, OFFICER: CO-CHIEF EXECUTIVE OFFICER
Klee Justin B.
Purchase · 60.0K shares
2026-08-18
★
OFFICER: CHIEF MEDICAL OFFICER
Bedrosian Camille L
Purchase · 22.8K shares
2026-08-18
★
OFFICER: CHIEF FINANCIAL OFFICER
FRATES JAMES M
Purchase · 22.8K shares
2026-08-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OUTPERFORM 2
7 GRADES IN THE LAST 12 MONTHS
Mizuho OUTPERFORM Guggenheim BUY Baird OUTPERFORM HC Wainwright & Co. BUY Citigroup BUY B of A Securities BUY Goldman Sachs BUY

SECTORS PEERS

PEERPRICE
RLAY$18.77COMPARE
ATAI$7.29COMPARE
PGEN$6.95COMPARE
NKTR$72.52COMPARE
INBX$123.41COMPARE
SNDX$19.54COMPARE
ORIC$13.24COMPARE
IMTX$9.45COMPARE